Disseminated progression of glioblastoma after treatment with bevacizumab

Clinical Neurology and Neurosurgery

Volumn 115, Issue 9, 2013, Pages 1795-1801

  Bloch, Orin ^a   Safaee, Michael ^a   Sun, Matthew Z ^a   Butowski, Nicholas A ^a   McDermott, Michael W ^a   Berger, Mitchel S ^a   Aghi, Manish K ^a   Parsa, Andrew T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bevacizumab; Craniotomy; Glioblastoma; Progression

Indexed keywords

BEVACIZUMAB; ERLOTINIB; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CRANIOTOMY; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TUMOR GROWTH; TUMOR RECURRENCE;

BEVACIZUMAB; CRANIOTOMY; GLIOBLASTOMA; PROGRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; KARNOFSKY PERFORMANCE STATUS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; NEUROSURGICAL PROCEDURES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84887622193     PISSN: 03038467     EISSN: 18726968     Source Type: Journal    
DOI: 10.1016/j.clineuro.2013.04.017     Document Type: Article

References (35)

1. R. Stupp, W.P. Mason, M.J. van den Bent, M. Weller, B. Fisher, and M.J. Taphoorn Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma New England Journal of Medicine 352 2005 987 996
2. E.T. Wong, K.R. Hess, M.J. Gleason, K.A. Jaeckle, A.P. Kyritsis, and M.D. Prados Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials Journal of Clinical Oncology 17 1999 2572 2578
3. K.R. Lamborn, W.K. Yung, S.M. Chang, P.Y. Wen, T.F. Cloughesy, and L.M. DeAngelis Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas Neuro-oncology 10 2008 162 170
4. K. Miller, M. Wang, J. Gralow, M. Dickler, M. Cobleigh, and E.A. Perez Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer New England Journal of Medicine 357 2007 2666 2676
5. J.C. Yang, L. Haworth, R.M. Sherry, P. Hwu, D.J. Schwartzentruber, and S.L. Topalian A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer New England Journal of Medicine 349 2003 427 434
6. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, and W. Heim Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer New England Journal of Medicine 350 2004 2335 2342
7. B.J. Giantonio, P.J. Catalano, N.J. Meropol, P.J. O'Dwyer, E.P. Mitchell, and S.R. Alberts Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 Journal of Clinical Oncology 25 2007 1539 1544
8. A. Sandler, R. Gray, M.C. Perry, J. Brahmer, J.H. Schiller, and A. Dowlati Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer New England Journal of Medicine 355 2006 2542 2550
9. J.J. Vredenburgh, A. Desjardins, J.E. Herndon 2nd, J. Marcello, D.A. Reardon, and J.A. Quinn Bevacizumab plus irinotecan in recurrent glioblastoma multiforme Journal of Clinical Oncology 25 2007 4722 4729
10. H.S. Friedman, M.D. Prados, P.Y. Wen, T. Mikkelsen, D. Schiff, and L.E. Abrey Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma Journal of Clinical Oncology 27 2009 4733 4740
11. H.S. Friedman, W.P. Petros, A.H. Friedman, L.J. Schaaf, T. Kerby, and J. Lawyer Irinotecan therapy in adults with recurrent or progressive malignant glioma Journal of Clinical Oncology 17 1999 1516 1525
12. T.F. Cloughesy, E. Filka, J. Kuhn, G. Nelson, F. Kabbinavar, and H. Friedman Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen Cancer 97 2003 2381 2386
13. T.N. Kreisl, L. Kim, K. Moore, P. Duic, C. Royce, and I. Stroud Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma Journal of Clinical Oncology 27 2009 740 745
14. F.M. Iwamoto, L.E. Abrey, K. Beal, P.H. Gutin, M.K. Rosenblum, and V.E. Reuter Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma Neurology 73 2009 1200 1206
15. A.D. Norden, G.S. Young, K. Setayesh, A. Muzikansky, R. Klufas, and G.L. Ross Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence Neurology 70 2008 779 787
16. J.F. de Groot, G. Fuller, A.J. Kumar, Y. Piao, K. Eterovic, and Y. Ji Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice Neuro-oncology 12 2010 233 242
17. A. Narayana, J.G. Golfinos, I. Fischer, S. Raza, P. Kelly, and E. Parker Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma International Journal of Radiation Oncology, Biology, Physics 72 2008 383 389
18. M.C. Chamberlain Radiographic patterns of relapse in glioblastoma Journal of Neuro-oncology 101 2011 319 323
19. A. Narayana, P. Kelly, J. Golfinos, E. Parker, G. Johnson, and E. Knopp Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival Journal of Neurosurgery 110 2009 173 180
20. A. Narayana, S.D. Kunnakkat, P. Medabalmi, J. Golfinos, E. Parker, and E. Knopp Change in pattern of relapse after antiangiogenic therapy in high-grade glioma International Journal of Radiation Oncology, Biology, Physics 82 2012 77 82
21. W.B. Pope, Q. Xia, V.E. Paton, A. Das, J. Hambleton, and H.J. Kim Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab Neurology 76 2011 432 437
22. A. Wick, N. Dorner, N. Schafer, S. Hofer, S. Heiland, and D. Schemmer Bevacizumab does not increase the risk of remote relapse in malignant glioma Annals of Neurology 69 2011 586 592
23. R.M. Zuniga, R. Torcuator, R. Jain, J. Anderson, T. Doyle, and S. Ellika Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan Journal of Neuro-oncology 91 2009 329 336
24. P.Y. Wen, D.R. Macdonald, D.A. Reardon, T.F. Cloughesy, A.G. Sorensen, and E. Galanis Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group Journal of Clinical Oncology 28 2010 1963 1972
25. J. Gallego Perez-Larraya, M. Lahutte, G. Petrirena, G. Reyes-Botero, A. Gonzalez-Aguilar, and C. Houillier Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria Neuro-oncology 14 2012 667 673
26. K.V. Ballman, J.C. Buckner, P.D. Brown, C. Giannini, P.J. Flynn, and B.R. LaPlant The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme Neuro-oncology 9 2007 29 38
27. A.D. Norden, J. Drappatz, A. Muzikansky, K. David, M. Gerard, and M.B. McNamara An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma Journal of Neuro-oncology 92 2009 149 155
28. P.H. Gutin, F.M. Iwamoto, K. Beal, N.A. Mohile, S. Karimi, and B.L. Hou Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas International Journal of Radiation Oncology, Biology, Physics 75 2009 156 163
29. J.J. Vredenburgh, A. Desjardins, D.A. Reardon, K.B. Peters, J.E. Herndon 2nd, and J. Marcello The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma Clinical Cancer Research 17 2011 4119 4124
30. A. Lai, A. Tran, P.L. Nghiemphu, W.B. Pope, O.E. Solis, and M. Selch Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme Journal of Clinical Oncology 29 2011 142 148
31. O.L. Chinot, T. de La Motte Rouge, N. Moore, A. Zeaiter, A. Das, and H. Phillips AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme Advances in Therapy 28 2011 334 340
32. A.J. Clark, N.A. Butowski, S.M. Chang, M.D. Prados, J. Clarke, and M.Y. Polley Impact of bevacizumab chemotherapy on craniotomy wound healing Journal of Neurosurgery 114 2011 1609 1616
33. M. DeLay, A. Jahangiri, W.S. Carbonell, Y.L. Hu, S. Tsao, and M.W. Tom Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy Clinical Cancer Research 18 2012 2930 2942
34. J.J. Vredenburgh, A. Desjardins, J.P. Kirkpatrick, D.A. Reardon, K.B. Peters, and J.E. Herndon 2nd Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme International Journal of Radiation Oncology, Biology, Physics 82 2012 58 66
35. A. Narayana, D. Gruber, S. Kunnakkat, J.G. Golfinos, E. Parker, and S. Raza A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma Journal of Neurosurgery 116 2012 341 345